ADiTx Therapeutics, Inc. Stock News

Source: motorolka / Shutterstock.com Aditxt (NASDAQ: ADTX ) stock is in the spotlight after the company implemented a reverse stock split yesterday. Down 16% as of this writing, today's movement in A

Here's what you need to know about buying penny stocks today The post Top Penny Stocks to Watch After the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.

Are you using these trends to make money with penny stocks? The post Stock Market Trends, Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Can these penny stocks make gains this week? The post Hot Penny Stocks to Buy Today?

ADTX stock is soaring after the company reported positive results from a preclinical toxicology test this morning. The post Why Is Aditxt (ADTX) Stock Up 74% Today?

Aditxt Inc's (NASDAQ: ADTX) therapeutic program Adimune has completed a toxicology study indicating a favorable safety profile of ADI-100 for rejection of transplanted organs, skin allografting, au

Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News an

Penny stocks under $1 to watch in April 2022 The post Best Penny Stocks For April 2022? 4 Under $1 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX) announced today it is participating in Edison Group's Open House Event, scheduled to take place virtuall

Aditxt Inc (ADTX) shares closed today at 0.4% above its 52 week low of $0.45, giving the company a market cap of $6M. The stock is currently down 12.5% year-to-date, down 80.0% over the past 12 months, and down 90.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 75.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 313.9% The company's stock price performance over the past 12 months lags the peer average by 162.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

ADiTx Therapeutics (NASDAQ:ADTX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report issued on Friday, Zacks.com reports. According to Zacks, Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx []

ADiTx Therapeutics (NASDAQ:ADTX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through []

Aditxt Inc (NASDAQ: ADTX) has priced an underwritten public offering of 16.575 million units, consisting of common shares and warrants to purchase up to 16.575 million shares at $1.05 per unit for

The stock price of Aditxt, Inc. (Nasdaq: ADTX) fell by over 18% pre-market today. This is why it happened.